Sorafenib has previously been reported to reduce the proportion of CD8+PD-1+ ‘exhausted’ T cells in the tumor microenvironment [8], therefore we next explored whether combinatorial therapy could potentially enhance this beneficial drug effect. Here, CD8A is linked to neoplasm.